[go: up one dir, main page]

MX2017015740A - Moduladores de ror gamma (ror?). - Google Patents

Moduladores de ror gamma (ror?).

Info

Publication number
MX2017015740A
MX2017015740A MX2017015740A MX2017015740A MX2017015740A MX 2017015740 A MX2017015740 A MX 2017015740A MX 2017015740 A MX2017015740 A MX 2017015740A MX 2017015740 A MX2017015740 A MX 2017015740A MX 2017015740 A MX2017015740 A MX 2017015740A
Authority
MX
Mexico
Prior art keywords
calkyl
cycloalkyl
ror
cheterocycloalkyl
cheteroaryl
Prior art date
Application number
MX2017015740A
Other languages
English (en)
Other versions
MX374728B (es
Inventor
Maria Gerardus Barbara Cals Joseph
Bernardus Nabuurs Sander
Original Assignee
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv filed Critical Lead Pharma Holding Bv
Publication of MX2017015740A publication Critical patent/MX2017015740A/es
Publication of MX374728B publication Critical patent/MX374728B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de acuerdo con la Fórmula I (ver Fórmula) o una de sus sales farmacéuticamente aceptables, en la que - A11 - A14 son N o CR11, CR12, CR13, CR14, respectivamente, con la condición de que no más de dos de las cuatro posiciones A puedan ser simultáneamente N; - R1 es Calquilo(2-6), Ccicloalquilo(3-6), Ccicloalquilo(3-6)Calquil o(1-3), (di)Ccicloalquilo(3-6)amino or (di)(Ccicloalquilo(3-6)Calq uilo(1-3))amino; R5 es H, hidroxietilo, metoxietilo, Calquilo(1-6), Carilo(6-10), Carilo(6-10)Calquilo(1-3), Cheteroarilo(1-9), Cheteroarilo(1-9)Calquilo(1-3), Ccicloalquilo(3-6), Ccicloalquilo(3-6)Calquilo(1-3), Cheterocicloalquilo(2-5) or Cheterocicloalquilo(2-5)-Calquilo(1-3) ; - el grupo sulfonilo con R1 se halla representado por uno de R7, R8 o R9 - R15 es H, Calquilo(1-6), Ccicloalquilo(3-6), Ccicloalquilo(3-6)Calquilo(1-3), Carilo(6-10), Carilo(6-10)Calquilo(1-3), Cheteroarilo(1-9), Cheteroarilo(1-9)Calquilo(1-3), Cheterocicloalquilo(2-5) o Cheterocicloalquilo(2-5)Calquilo(1-3); - y R16 es Calquilo(1-6), Ccicloalquilo(3-6), Ccicloalquilo(3-6)Calquilo(1-3), Carilo(6-10), Carilo(6-10)Calquilo(1-3), Cheteroarilo(1-9), Cheteroarilo(1-9)Calquilo(1-3), Cheterocicloalquilo(2-5) o Cheterocicloalquilo(2-5)Calquilo(1-3). Los compuestos se pueden usar como inhibidores de ROR? y son útiles para el tratamiento de enfermedades mediadas por ROR?.
MX2017015740A 2015-06-05 2016-06-03 MODULADORES DE ROR GAMMA (RORy). MX374728B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170765.0A EP3101009A1 (en) 2015-06-05 2015-06-05 Ror gamma (rory) modulators
PCT/EP2016/062701 WO2016193461A1 (en) 2015-06-05 2016-06-03 ROR GAMMA (RORγ) MODULATORS

Publications (2)

Publication Number Publication Date
MX2017015740A true MX2017015740A (es) 2018-04-24
MX374728B MX374728B (es) 2025-03-06

Family

ID=53284143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015740A MX374728B (es) 2015-06-05 2016-06-03 MODULADORES DE ROR GAMMA (RORy).

Country Status (15)

Country Link
US (1) US10556866B2 (es)
EP (2) EP3101009A1 (es)
JP (1) JP6754777B2 (es)
KR (1) KR102576004B1 (es)
CN (1) CN108430974B (es)
AR (1) AR104880A1 (es)
AU (1) AU2016273353B2 (es)
CA (1) CA2988002C (es)
ES (1) ES2783824T3 (es)
IL (1) IL256038B (es)
MX (1) MX374728B (es)
PL (1) PL3303293T3 (es)
PT (1) PT3303293T (es)
RU (1) RU2735546C2 (es)
WO (1) WO2016193461A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804587QA (en) 2015-12-15 2018-06-28 Astrazeneca Ab Isoindole compounds
AR109042A1 (es) 2016-07-14 2018-10-24 Cadila Healthcare Ltd COMPUESTOS MODULARES DE RORg
US20190152962A1 (en) 2016-07-14 2019-05-23 Cadila Healthcare Limited Cyclopropyl derivatives as ror-gamma modulators
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
JP2020142989A (ja) * 2017-06-21 2020-09-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
CN109593068B (zh) * 2017-09-30 2022-12-27 广东东阳光药业有限公司 一种RORγ抑制剂的中间体及其制备方法
CN108840800A (zh) * 2018-05-28 2018-11-20 上海华堇生物技术有限责任公司 一种苯基硝基乙酮的新制备方法
CN117800904A (zh) * 2018-11-27 2024-04-02 正大天晴药业集团股份有限公司 含有磺酰基结构的RORγ抑制剂
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
US20250091996A1 (en) 2023-09-15 2025-03-20 King Faisal University 2-(1h-imidazole-1-carbonyl)benzoic acid as an anticancer compound
CN117384004B (zh) * 2023-12-11 2024-03-29 山东国邦药业有限公司 一种2,4-二氯氟苯的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
WO2012028100A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013161851A1 (ja) 2012-04-24 2013-10-31 中外製薬株式会社 ベンズアミド誘導体
JP6225178B2 (ja) * 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
US10035790B2 (en) * 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) * 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
WO2015145371A1 (en) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)

Also Published As

Publication number Publication date
AR104880A1 (es) 2017-08-23
AU2016273353B2 (en) 2020-08-27
PT3303293T (pt) 2020-04-09
PL3303293T3 (pl) 2020-10-05
MX374728B (es) 2025-03-06
EP3303293B1 (en) 2020-02-05
CA2988002C (en) 2023-08-08
CN108430974A (zh) 2018-08-21
US10556866B2 (en) 2020-02-11
CN108430974B (zh) 2021-09-17
EP3101009A1 (en) 2016-12-07
IL256038A (en) 2018-01-31
RU2735546C2 (ru) 2020-11-03
US20180162815A1 (en) 2018-06-14
IL256038B (en) 2021-02-28
WO2016193461A1 (en) 2016-12-08
RU2017145930A (ru) 2019-07-09
JP2018518480A (ja) 2018-07-12
ES2783824T3 (es) 2020-09-18
BR112017026223A2 (pt) 2018-09-11
AU2016273353A1 (en) 2018-01-04
KR20180040559A (ko) 2018-04-20
RU2017145930A3 (es) 2019-09-27
CA2988002A1 (en) 2016-12-08
EP3303293A1 (en) 2018-04-11
JP6754777B2 (ja) 2020-09-16
KR102576004B1 (ko) 2023-09-06

Similar Documents

Publication Publication Date Title
MX2017015740A (es) Moduladores de ror gamma (ror?).
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
MX2021009673A (es) Moduladores de ror-gamma.
CU20200080A7 (es) Kit que comprende un inhibidor de lats para el suministro ocular
PH12016501066A1 (en) ROR GAMMA (ROYy) MODULATORS
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36708A (es) MODULADORES DE ROR GAMMA (RORy)
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY36709A (es) Moduladores de ror gamma (ror¿)
MX2017015743A (es) Moduladores de ror gamma (ror?).
CL2021001461A1 (es) Moduladores de trex1
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MX2017015739A (es) Moduladores de ror gamma (ror?).
AR107588A1 (es) Imidazolil-carboxamidas sustituidas como plaguicidas
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2019007186A2 (es) Moduladores de ror gamma (rorγ)
AR108312A1 (es) 2-alquilimidazolilcarboxamidas sustituidas como pesticidas

Legal Events

Date Code Title Description
FG Grant or registration